STAT3 inhibitor
View Patent ↗Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.
1. A compound having the following structure:
wherein R 5 is selected from the group consisting of alkyl (C1-14) , substituted alkyl (C1-14) , —H,
wherein R 3 is halogen, —OH, or —H; wherein R 7 is —H or R 1 ; wherein R 8 and R 9 are each independently —H or halogen; wherein R 6 is —H or —O—CH 3 ; wherein X 2 is —C(O)—; wherein R″″ is —H, —CF 3 , —NO 2 , —CN, halogen, alkyl (C1-12) , alkoxy (C1-12) , aryl (C6-12) , heteroaryl (C4-12) , substituted carboxylates (C1-C12) , amido (C1-C12) , substituted alkylamino (C1-C12) , or —S(O) 2- X 3 ; wherein X 3 is —OH, —NH 2 , —OCH 3 , —OCH 2 CH 3 , —C(O)CH 3 , —NHCH 3 , —NHCH 2 CH 3 , —(CH 3 ) 2 , —C(O)NH 2 ,or —OC(O)CH 3 ;
wherein R 1 is selected from the group consisting of substituted or unsubstituted alkyl (C1-12) , substituted or unsubstituted heterocycloalkyl (C4-12) , acyl (C 1-C6) , alkylamino (C1-6) , alkoxyamino (C1-6) ,
wherein X 1 is —O— or —NH—; wherein n=0, 1, 2, 3, 4, or 5; wherein R′ is selected from the group consisting of substituted or unsubstituted alkyl (C1-6) , alkylamino (C1-6) , halogen, —OH, amido (C1-12) , alkyl sulfonylamino (C1-12) ,
substituted or unsubstituted heterocycloalkyl (C4-12) ; wherein R 11 and R 12 are each independently —H or alkyl (C1-6) ; wherein R″ is —H, —OH, —NH 2 , or halogen; wherein R″′ is alkyl (C1-6) ;
or a salt thereof.
2. The compound of claim 1 , wherein the compound is comprised in a pharmaceutical composition or a pharmaceutically acceptable carrier.
3. The compound of claim 1 , wherein the compound has the structure
4. The compound of claim 1 , wherein R 6 is —H.
5. The compound of claim 1 , wherein R 5 is
wherein n is 1, 2, 3, or 4.
6. The compound of claim 5 , wherein R″″ is aryl (C6-12) or heteroaryl (C4-12) , wherein said aryl (C6-12) or heteroaryl (C4-12) is fused or unfused.
7. The compound of claim 1 , wherein R 5 is selected form the group consisting of
8. The compound of claim 1 , wherein R 5 is
9. The compound of claim 8 , wherein R 3 is —Cl.
10. The compound of claim 8 , wherein R 7 is selected from the group consisting of —H, substituted alkyl (C1-14) , substituted heterocycloalkyl (C4-12) , substituted or unsubstituted alkylamino (C1-14) , or alkoxyamino (C1-12) .
11. The compound of claim 10 , wherein R 7 is selected from the group consisting of —H,
12. The compound of claim 1 , wherein the compound is:
or a salt thereof.
13. The compound of claim 1 , wherein the compound has the structure
14. The compound of claim 1 , wherein R 6 is —O—CH 3 .
15. The compound of claim 14 , wherein the compound has the structure:
16. A method of treating cancer in a subject comprising administering a pharmaceutically effective amount of a compound of claim 1 to the subject to treat the cancer wherein the cancer is selected from pancreatic cancer, breast cancer, lung cancer, head/neck cancer, brain cancer, liver cancer, colon cancer and leukemia.
17. A method of treating inflammation in a subject comprising administering a pharmaceutically effective amount of a compound of claim 1 to the subject to treat the inflammation.
18. The compound of claim 12 , wherein the compound is